Orion Corporation (ORNAV.HE)

Executive Summary

Orion Corporation is a Finnish pharmaceutical company with a century-long history, specializing in CNS disorders, oncology, and respiratory diseases. The company boasts a substantial R&D pipeline of 112 drug candidates, balancing proprietary projects with partnered programs. Orion's vertically integrated operations span from development to commercial manufacturing, supporting a robust portfolio of both in-house specialty products and contract manufacturing services. The company is publicly traded on Nasdaq Helsinki and generates a significant portion of sales outside Finland. Despite a mature product portfolio, Orion is investing in next-generation therapies, including novel formulations and drug-device combinations, positioning itself for sustained growth in key therapeutic areas.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 readout for ODM-201 (darolutamide) in prostate cancer75% success
• Q1 2027Regulatory approval for Easyhaler formulation for COPD in Europe85% success
• Q2 2026Partnership announcement for early-stage CNS asset60% success